These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
256 related articles for article (PubMed ID: 11393591)
21. Escitalopram versus sertraline in the treatment of major depressive disorder: a randomized clinical trial. Ventura D; Armstrong EP; Skrepnek GH; Haim Erder M Curr Med Res Opin; 2007 Feb; 23(2):245-50. PubMed ID: 17288677 [TBL] [Abstract][Full Text] [Related]
22. Escitalopram in the treatment of adolescent depression: a randomized, double-blind, placebo-controlled extension trial. Findling RL; Robb A; Bose A J Child Adolesc Psychopharmacol; 2013 Sep; 23(7):468-80. PubMed ID: 24041408 [TBL] [Abstract][Full Text] [Related]
23. Effective dose of escitalopram in moderate versus severe DSM-IV major depression. Bech P; Andersen HF; Wade A Pharmacopsychiatry; 2006 Jul; 39(4):128-34. PubMed ID: 16871468 [TBL] [Abstract][Full Text] [Related]
24. A comparative study of the efficacy of acute and continuation treatment with escitalopram versus duloxetine in patients with major depressive disorder. Wade A; Gembert K; Florea I Curr Med Res Opin; 2007 Jul; 23(7):1605-14. PubMed ID: 17559755 [TBL] [Abstract][Full Text] [Related]
25. A randomised study comparing escitalopram with venlafaxine XR in primary care patients with major depressive disorder. Montgomery SA; Huusom AK; Bothmer J Neuropsychobiology; 2004; 50(1):57-64. PubMed ID: 15179022 [TBL] [Abstract][Full Text] [Related]
26. Single i.v. ketamine augmentation of newly initiated escitalopram for major depression: results from a randomized, placebo-controlled 4-week study. Hu YD; Xiang YT; Fang JX; Zu S; Sha S; Shi H; Ungvari GS; Correll CU; Chiu HF; Xue Y; Tian TF; Wu AS; Ma X; Wang G Psychol Med; 2016 Feb; 46(3):623-35. PubMed ID: 26478208 [TBL] [Abstract][Full Text] [Related]
27. Randomized placebo-controlled trial of escitalopram and venlafaxine XR in the treatment of generalized anxiety disorder. Bose A; Korotzer A; Gommoll C; Li D Depress Anxiety; 2008; 25(10):854-61. PubMed ID: 18050245 [TBL] [Abstract][Full Text] [Related]
28. Escitalopram 10 mg/day is effective and well tolerated in a placebo-controlled study in depression in primary care. Wade A; Michael Lemming O; Bang Hedegaard K Int Clin Psychopharmacol; 2002 May; 17(3):95-102. PubMed ID: 11981349 [TBL] [Abstract][Full Text] [Related]
30. Baseline severity of depression predicts antidepressant drug response relative to escitalopram. Kilts CD; Wade AG; Andersen HF; Schlaepfer TE Expert Opin Pharmacother; 2009 Apr; 10(6):927-36. PubMed ID: 19317630 [TBL] [Abstract][Full Text] [Related]
31. Citalopram and escitalopram in the treatment of major depressive disorder: a pooled analysis of 3 clinical trials. Li H; Li T; Li G; Luo J Ann Clin Psychiatry; 2014 Nov; 26(4):281-7. PubMed ID: 25401715 [TBL] [Abstract][Full Text] [Related]
32. Superiority of escitalopram to paroxetine in the treatment of depression. Kasper S; Baldwin DS; Larsson Lönn S; Boulenger JP Eur Neuropsychopharmacol; 2009 Apr; 19(4):229-37. PubMed ID: 19185467 [TBL] [Abstract][Full Text] [Related]
33. Escitalopram dose-response revisited: an alternative psychometric approach to evaluate clinical effects of escitalopram compared to citalopram and placebo in patients with major depression. Bech P; Tanghøj P; Cialdella P; Andersen HF; Pedersen AG Int J Neuropsychopharmacol; 2004 Sep; 7(3):283-90. PubMed ID: 15320956 [TBL] [Abstract][Full Text] [Related]
34. A randomized controlled trial of the efficacy and safety of lisdexamfetamine dimesylate as augmentation therapy in adults with residual symptoms of major depressive disorder after treatment with escitalopram. Trivedi MH; Cutler AJ; Richards C; Lasser R; Geibel BB; Gao J; Sambunaris A; Patkar AA J Clin Psychiatry; 2013 Aug; 74(8):802-9. PubMed ID: 24021497 [TBL] [Abstract][Full Text] [Related]
35. [Safety and efficacy of oral escitalopram as continuation treatment of intravenous citalopram, in patients with major depressive disorder--the navigade switch study]. Schmitt L; Arbus C; Tonnoir B Encephale; 2006; 32(2 Pt 1):270-7. PubMed ID: 16910629 [TBL] [Abstract][Full Text] [Related]
36. Cost-effectiveness of escitalopram vs. citalopram in major depressive disorder. Fantino B; Moore N; Verdoux H; Auray JP Int Clin Psychopharmacol; 2007 Mar; 22(2):107-15. PubMed ID: 17293711 [TBL] [Abstract][Full Text] [Related]
37. Escitalopram in the treatment of adolescent depression: a randomized placebo-controlled multisite trial. Emslie GJ; Ventura D; Korotzer A; Tourkodimitris S J Am Acad Child Adolesc Psychiatry; 2009 Jul; 48(7):721-729. PubMed ID: 19465881 [TBL] [Abstract][Full Text] [Related]
38. Efficacy and safety of escitalopram versus citalopram in major depressive disorder: a 6-week, multicenter, randomized, double-blind, flexible-dose study. Ou JJ; Xun GL; Wu RR; Li LH; Fang MS; Zhang HG; Xie SP; Shi JG; Du B; Yuan XQ; Zhao JP Psychopharmacology (Berl); 2011 Feb; 213(2-3):639-46. PubMed ID: 20340011 [TBL] [Abstract][Full Text] [Related]
39. Escitalopram for severe asthma and major depressive disorder: a randomized, double-blind, placebo-controlled proof-of-concept study. Brown ES; Howard C; Khan DA; Carmody TJ Psychosomatics; 2012; 53(1):75-80. PubMed ID: 22221724 [TBL] [Abstract][Full Text] [Related]
40. Escitalopram for the prevention of peginterferon-α2a-associated depression in hepatitis C virus-infected patients without previous psychiatric disease: a randomized trial. Schaefer M; Sarkar R; Knop V; Effenberger S; Friebe A; Heinze L; Spengler U; Schlaepfer T; Reimer J; Buggisch P; Ockenga J; Link R; Rentrop M; Weidenbach H; Fromm G; Lieb K; Baumert TF; Heinz A; Discher T; Neumann K; Zeuzem S; Berg T Ann Intern Med; 2012 Jul; 157(2):94-103. PubMed ID: 22801672 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]